VetACE is indicated for the treatment of heart failure in dogs, and chronic renal insufficiency and hypertrophic cardiomyopathy in cats.

Dogs

VetACE is indicated for the treatment of left sided heart failure in dogs, most commonly resulting from mitral regurgitation (endocardiosis) and dilated cardiomyopathy (DCM). VetACE, by inhibiting the renin angiotensin aldosterone (RAA) system, minimises the undesirable effects of vasoconstriction and sodium retention mediated by this system. VetACE leads to an extension of the life span of dogs with heart failure and also improves clinical signs, notably a reduction in coughing, and improvement to the quality of life. VetACE may be used in combination therapy with diuretics, for example furosemide, digoxin and antiarrhythmic drugs as necessary.

Cats

VetACE is indicated for the treatment of chronic renal insufficiency in cats. In such cats, it reduces protein loss in urine and lowers systemic and intraglomerular blood pressure. It increases quality of life, particularly in advanced cases. VetACE increases the survival time in cats with a urinary protein/creatinine ratio (UPC) equal to or exceeding 0.8 before treatment, and improves the appetite in cats with a UPC ratio exceeding 1.0. It has some beneficial effects on clinical signs and cardiac remodelling in cats with feline hypertrophic cardiomyopathy (HCM) and is well tolerated. Most cases of HCM in cats will require other additional medications of which the most commonly prescribed will be a calcium channel blocker, for example diltiazem.